These two integrase inhibitors are associated with high blood sugar and diabetes.

Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

People who switched from tenofovir disoproxil fumarate to tenofovir alafenamide gained weight regardless of other meds.

Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.

This is especially the case for people globally who don’t have access to such newer regimens.

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.